The company's anti infective candidate molecules have completed preclinical pharmacological and preliminary safety evaluations, and all data meets expectations, supporting the next stage of development.
Significant progress has been made in preclinical research on candidate anti infective molecules
The anti infective candidate molecules independently deployed by the company have completed key preclinical pharmacological evaluations, and the data supports further development.
More News
Hong Kong Biopharmaceutical expands its functional food pipeline and deepens the layout of the health industry in Guangdong, Hong Kong, and MacauParticipate in international biomedical academic conferences and share cutting-edge research on new drugs and vaccinesCollaborate with research institutions on industry university research projects